SINGAPORE: BioNTech will shutter its vaccine manufacturing plant in Singapore by the end of February next year, the German biotechnology firm said on Thursday (Apr 2), following a “comprehensive review”.
The company has suffered losses in recent years and reported last month a net loss of €1.14 billion (US$1.31 billion) in 2025, compared with a €665 million loss in 2024.
“BioNTech made the strategic decision to close its planned Singapore site by the end of February 2027, as we continue to align capacity with our clinical portfolio and long-term strategic direction,” the COVID-19 vaccine maker told CNA.
“We recognise the significant contributions of our employees affected by these changes and are committed to supporting them through this transition.”
